Improving Post-discharge Antimicrobial Use

Status Recruiting

Clinical Trial Summary

One in five hospitalized patients is prescribed an antimicrobial at the time of discharge, and a large proportion of these post-discharge antimicrobials are unnecessary. The investigators will evaluate a novel method for reviewing post-discharge antimicrobial prescriptions in real-time with the goal of improving antimicrobial selection and duration.

Clinical Trial Description

Antimicrobial stewardship programs (ASPs) work to improve antibiotic prescribing within hospitals. ASPs often restrict their activities to inpatient antimicrobial-prescribing. However, at least 40% of all antimicrobial exposure associated with an acute-care hospital stay is prescribed at the time of hospital discharge (i.e., post-discharge). Post-discharge antimicrobials mediate clinical outcomes after discharge and may facilitate the spread of antimicrobial resistance. Several studies have shown that post-discharge antimicrobial use is often inappropriate. For example, using national VA data, the investigators found that 61% of fluoroquinolone treatment days were prescribed at hospital discharge; manual chart reviews at 9 hospitals found that 40% of these post-discharge fluoroquinolone prescriptions were either unnecessary or sub-optimal. Other studies have found that 53-79% of all post-discharge antimicrobials are either unnecessary or sub-optimal. Post-discharge antimicrobials are an important target for antimicrobial stewardship. However, inpatient stewardship metrics do not capture post-discharge antimicrobials and ASPs frequently do not evaluate these prescriptions. A 2016 VA survey found that less than 50% of hospitals routinely reviewed targeted antimicrobials at discharge. According to a 2016 survey in Michigan, only 17% of 48 hospitals had a process for reviewing outpatient antimicrobial orders at discharge. It is unclear how inpatient stewardship resources can be effectively leveraged to improve post-discharge antimicrobial use. If the goal is to improve post-discharge antimicrobial use, a potentially effective strategy may be an audit-and-feedback process focused solely on prescriptions for patients who will soon be discharged. In this trial, the investigators will evaluate the feasibility and effectiveness of such a process. ;

Study Design

Related Conditions & MeSH terms

Infections

Clinical Trial Details

NCT number	NCT05471726
Study type	Interventional
Source	Iowa City Veterans Affairs Medical Center
Contact	Daniel J Livorsi, MD
Phone	319-688-3871
Email	daniel-livorsi@uiowa.edu
Status	Recruiting
Phase	N/A
Start date	May 22, 2023
Completion date	December 19, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06055777` - Study of the Safety, Tolerability, and PK of SZEY-2108 Administered Intravenously to HVs in SAD and MAD Cohorts	Phase 1
Recruiting	`NCT05578196` - Fecal Microbial Transplantation in Critically Ill Patients With Severe Infections.	N/A
Recruiting	`NCT05793983` - S100A8/A9 and Innate Immunity in Liver Disease
Active, not recruiting	`NCT05963269` - The Effect of the Game on Students' Intramuscular Injection Skills	N/A
Not yet recruiting	`NCT06026852` - Validation of Betalactam ML Prediction Models - TDMAide	N/A
Not yet recruiting	`NCT02222779` - Quantification of Transition Metals	N/A
Completed	`NCT01976234` - Stored RBC Transfusion and Immonomodulation	N/A
Completed	`NCT02345135` - Susceptibility to Infections in Ataxia Telangiectasia	N/A
Completed	`NCT01530763` - Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Community Acquired Bacterial Pneumonia (CABP)	Phase 2/Phase 3
Completed	`NCT01158560` - A Trial of Vitamin D and Health Advice for the Prevention of Upper Respiratory Tract Infections	Phase 3
Completed	`NCT01176786` - Reusable Versus Disposable Draping System in Breast Reconstruction Surgery	N/A
Active, not recruiting	`NCT05284097` - Ad26.ZEBOV, MVA-BN-Filo Vaccination in Children and Adults Previously Vaccinated With Control in the EBOVAC-Salone Study	Phase 2
Enrolling by invitation	`NCT06055712` - Antibiotic Prophylaxis in Pediatric Open Fractures	Phase 4
Not yet recruiting	`NCT06338345` - Pharmacokinetics and Modelling of Beta-Lactam in ECMO-VA Patients	N/A
Not yet recruiting	`NCT06402292` - Surgical Treatment of Osteoarticular Infections Using Bioactive Bone Substitute	N/A
Recruiting	`NCT06002685` - Partners in Children's Health (CSN): A Randomized Trial of an Attachment Based Intervention	N/A
Completed	`NCT02802059` - E. Coli Nissle 1917 - Suspension for Infection Prophylaxis	Phase 3
Completed	`NCT05289674` - The Effect of Lactoferrin in High Calorie Formula on IL-6 and IL10 in Children With Failure to Thrive and Infection	N/A
Recruiting	`NCT05770765` - Creation of a Bank of Biological Materials and Associated Data Related to Patients With Infectious and Tropical Diseases
Completed	`NCT05389540` - Rural South and Southeast Asia Household Health Survey

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.